Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment

Induction of IL-17+ T Cell Trafficking and Development by IFN- : Mechanism and Pathological Relevance in Psoriasis

(2014) I. Kryczek et al.   JOURNAL OF IMMUNOLOGY

Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease

(2012) A. Buisson et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Paradoxical inflammation induced by anti-TNF agents in patients with IBD

(2012) Isabelle Cleynen et al.   Nature Reviews Gastroenterology & Hepatology

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

(2012) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

(2012) Craig Leonardi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of IL12B Gene Variants in Inflammatory Bowel Disease

(2012) Jürgen Glas et al.   PLoS One

Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature

(2011) G. Cullen et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Long-term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT-1 and -2 Extension Studies

(2011) Walter Reinisch et al.   INFLAMMATORY BOWEL DISEASES

Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: A report of 21 cases

(2011) Iván Guerra et al.   Journal of Crohns & Colitis

Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: The Mayo Clinic experience, 1998 to 2010

(2011) Eugenia Shmidt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47

(2011) Carl A Anderson et al.   NATURE GENETICS

The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans

(2011) Paola Di Meglio et al.   PLoS One

CEACAM6 Gene Variants in Inflammatory Bowel Disease

(2011) Jürgen Glas et al.   PLoS One

Functional Studies on the IBD Susceptibility Gene IL23R Implicate Reduced Receptor Function in the Protective Genetic Variant R381Q

(2011) Svetlana Pidasheva et al.   PLoS One

Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses

(2011) R. Sarin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Severe Skin Lesions Cause Patients With Inflammatory Bowel Disease to Discontinue Anti–Tumor Necrosis Factor Therapy

(2010) Jean–François Rahier et al.   Clinical Gastroenterology and Hepatology

Strong overexpression of CXCR3 axis components in childhood inflammatory bowel disease

(2010) Sebastian Schroepf et al.   INFLAMMATORY BOWEL DISEASES

Infliximab and adalimumab-induced psoriasis in Crohn's disease: A paradoxical side effect

(2010) Marisa Iborra et al.   Journal of Crohns & Colitis

A Naturally Occurring, Soluble Antagonist of Human IL-23 Inhibits the Development and In Vitro Function of Human Th17 Cells

(2010) R. Y. Yu et al.   JOURNAL OF IMMUNOLOGY

Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci

(2010) Andre Franke et al.   NATURE GENETICS

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

The NOD2 Single Nucleotide Polymorphisms rs2066843 and rs2076756 Are Novel and Common Crohn's Disease Susceptibility Gene Variants

(2010) Jürgen Glas et al.   PLoS One

Novel Genetic Risk Markers for Ulcerative Colitis in the IL2/IL21 Region Are in Epistasis With IL23R and Suggest a Common Genetic Background for Ulcerative Colitis and Celiac Disease

(2009) Jürgen Glas et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Cytokine imbalance with increased production of interferon-α in psoriasiform eruptions associated with antitumour necrosis factor-α treatments

(2009) J. Seneschal et al.   BRITISH JOURNAL OF DERMATOLOGY

Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease

(2009) S. Brand   GUT

Severe Legionella pneumophila pneumonia following infliximab therapy in a patient with Crohnʼs disease

(2009) Florian Beigel et al.   INFLAMMATORY BOWEL DISEASES

IFN-  Inhibits Human Th17 Cell Differentiation

(2009) V. S. Ramgolam et al.   JOURNAL OF IMMUNOLOGY

IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not

(2009) Kerstin Wolk et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21

(2009) Xue-Jun Zhang et al.   NATURE GENETICS

Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways

(2009) Rajan P Nair et al.   NATURE GENETICS

Hepatosplenic T-cell lymphoma in a patient with Crohn's disease

(2009) Florian Beigel et al.   Nature Reviews Gastroenterology & Hepatology

Psoriasis

(2009) Frank O. Nestle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor   therapy: results from the British Society for Rheumatology Biologics Register

(2008) M J Harrison et al.   ANNALS OF THE RHEUMATIC DISEASES

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY

The role of the novel Th17 cytokine IL-26 in intestinal inflammation

(2008) J Dambacher et al.   GUT

Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases

(2008) Justin M. Ko et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

A Genome-Wide Association Study of Psoriasis and Psoriatic Arthritis Identifies New Disease Loci

(2008) Ying Liu et al.   PLoS Genetics

Linking genetic susceptibility to Crohnʼs disease with Th17 cell function: IL-22 serum levels are increased in Crohnʼs disease and correlate with disease activity and IL23R genotype status

(2007) Silke Schmechel et al.   INFLAMMATORY BOWEL DISEASES

Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): Upregulated colonic IL-17F expression in active Crohnʼs disease and analysis of the IL17F p.His161Arg polymorphism in IBD

(2007) Julia Seiderer et al.   INFLAMMATORY BOWEL DISEASES